Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) FCF Margin (2016 - 2025)

Historic FCF Margin for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to 24.62%.

  • Amphastar Pharmaceuticals' FCF Margin rose 4800.0% to 24.62% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.66%, marking a year-over-year decrease of 78600.0%. This contributed to the annual value of 23.55% for FY2024, which is 9900.0% up from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported FCF Margin of 24.62% as of Q3 2025, which was up 4800.0% from 14.35% recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' FCF Margin peaked at 36.6% during Q1 2022, and registered a low of 4.14% during Q3 2021.
  • Moreover, its 5-year median value for FCF Margin was 22.07% (2023), whereas its average is 18.81%.
  • Its FCF Margin has fluctuated over the past 5 years, first crashed by -280700bps in 2022, then soared by 335700bps in 2023.
  • Amphastar Pharmaceuticals' FCF Margin (Quarter) stood at 27.76% in 2021, then tumbled by -76bps to 6.6% in 2022, then increased by 23bps to 8.1% in 2023, then grew by 10bps to 8.91% in 2024, then skyrocketed by 176bps to 24.62% in 2025.
  • Its FCF Margin was 24.62% in Q3 2025, compared to 14.35% in Q2 2025 and 14.3% in Q1 2025.